Who are Combined aspirin and multinutrient supplement's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/combined-aspirin-and-multinutrient-supplement.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Combined aspirin and multinutrient supplement — Competitive Intelligence Brief

Combined aspirin and multinutrient supplement (Combined aspirin and multinutrient supplement) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiplatelet agent combined with nutritional supplement. Area: Cardiovascular.

phase 3 Antiplatelet agent combined with nutritional supplement COX-1/COX-2 (aspirin); multiple micronutrient targets (multinutrient component) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Combined aspirin and multinutrient supplement (Combined aspirin and multinutrient supplement) — UMC Utrecht. Aspirin reduces platelet aggregation and inflammation while multinutrients provide essential vitamins and minerals to support cardiovascular health and metabolic function.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Combined aspirin and multinutrient supplement TARGET	Combined aspirin and multinutrient supplement	UMC Utrecht	phase 3	Antiplatelet agent combined with nutritional supplement	COX-1/COX-2 (aspirin); multiple micronutrient targets (multinutrient component)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiplatelet agent combined with nutritional supplement class)

UMC Utrecht · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Combined aspirin and multinutrient supplement — Competitive Intelligence Brief. https://druglandscape.com/ci/combined-aspirin-and-multinutrient-supplement. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab